TSS
PGNX

Two Sigma Securities’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Two Sigma Securities’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-17,172
Closed -$109K – 1031
2016
Q3 		$109K Buy
+17,172
New +$104K 0.04% 512

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Two Sigma Securities's PGNX Position: Q4 2016 in Review

Two Sigma Securities sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2016, closing a stake of 17,172 shares — an estimated $109K sold.

Two Sigma Securities first reported a position in PGNX in Q3 2016 and held it in 1 quarter. The position peaked at $109K in Q3 2016. 126 funds tracked by Wall St. Rank hold PGNX as of Q4 2016.

  • Two Sigma Securities reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • Two Sigma Securities sold 17,172 Progenics Pharmaceuticals Inc shares in Q4 2016, an estimated $109K.
  • Two Sigma Securities first reported a position in Progenics Pharmaceuticals Inc in Q3 2016 and held it in 1 quarter.
  • Two Sigma Securities's Progenics Pharmaceuticals Inc position peaked at $109K in Q3 2016.
  • 126 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2016.

Based on Two Sigma Securities's 13F filing for Q4 2016, filed 14 Feb 2017.